Analyst Research

Report Title Price
Thomson Reuters Stock Report - NUPATHE INCORPORATION (PATH-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
NUPATHE INC (PATH) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
Nupathe Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
ValuEngine Detailed Valuation Report for PATH
Provider: ValuEngine, Inc.
$127.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

NuPathe Inc To Cut Half Its Jobs To Conserve Cash-Reuters


Tuesday, 9 Oct 2012 08:31am EDT 

Reuters reported that NuPathe Inc said it would cut half of its workforce to reduce costs and focus on the regulatory approval of its experimental migraine patch. The Company said it will reduce expenses related to the marketing of the pain patch and on earlier-stage drug candidates. 

Latest Developments for Nupathe Inc

Latest Key Developments in Pharmaceuticals

Company Quote

Nupathe Inc
(PATH.OQ)
3.17
-0.03 -0.94%
2:47pm EDT